Amy Elazzouzi Sells 1,404 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) SVP Amy Elazzouzi sold 1,404 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total transaction of $10,881.00. Following the sale, the senior vice president now owns 82,278 shares of the company's stock, valued at approximately $637,654.50. This represents a 1.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 21st, Amy Elazzouzi sold 1,001 shares of Aura Biosciences stock. The shares were sold at an average price of $7.67, for a total value of $7,677.67.

Aura Biosciences Trading Down 1.6 %

Shares of AURA stock traded down $0.12 during trading hours on Friday, hitting $7.51. The company's stock had a trading volume of 146,728 shares, compared to its average volume of 138,951. The business has a fifty day moving average of $7.99 and a 200-day moving average of $8.73. Aura Biosciences, Inc. has a twelve month low of $6.63 and a twelve month high of $12.38. The stock has a market cap of $375.12 million, a price-to-earnings ratio of -4.34 and a beta of 0.29.

Wall Street Analysts Forecast Growth

AURA has been the topic of several recent research reports. Lifesci Capital raised shares of Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $23.00.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of AURA. ProShare Advisors LLC acquired a new position in shares of Aura Biosciences in the fourth quarter worth $127,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Aura Biosciences by 27.7% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,516 shares of the company's stock valued at $1,122,000 after purchasing an additional 29,618 shares in the last quarter. Ensign Peak Advisors Inc lifted its holdings in Aura Biosciences by 43.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company's stock valued at $3,212,000 after purchasing an additional 118,000 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Aura Biosciences by 56.7% during the 4th quarter. Deutsche Bank AG now owns 44,085 shares of the company's stock worth $362,000 after purchasing an additional 15,951 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Aura Biosciences by 20.5% during the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company's stock worth $422,000 after buying an additional 8,709 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company's stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.